|
| Efficacy and safety of compound Ejiao Jiang for bone marrow suppression after cancer chemotherapy: A systematic review |
| Hits 1459 Download times 1202 Received:October 20, 2018 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2019.05.13 |
| Key Words
compound Ejiao Jiang;chemotherapy;bone marrow suppression;systematic review;Meta-analysis;randomized controlled trial |
| Author Name | Affiliation | E-mail | | ZHANG Mingyan | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHENG Wenke | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | YANG Fengwen | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LI Yue | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHANG Lishuang | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHAO Hongjie | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | JI Zhaochen | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Hui | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ZHANG Junhua | Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | zjhtcm@foxmail.com |
|
| Abstract
|
| [Objective] To systematically evaluate the efficacy and safety of combination of chemotherapy and compound Ejiao Jiang for bone marrow suppression after cancer chemotherapy.[Methods] We searched databases to collect RCTs of compound Ejiao Jiang combined with chemotherapy from inception to March 2017. Two researchers independently screened literature,extracted data and evaluated the risk of bias,and did Meta-analysis by RevMan 5.3.[Results] A total of 17 RCTs,involving 7 outcomes and 1 139 patients were included. The results of Meta-analysis showed that:compared with the chemotherapeutic group,compound Ejiao Jiang group had a higher count of white blood cell[MD=-0.71,95% CI(-1.14,-0.28),P=0.001;OR=0.24,95% CI(0.13,0.48),P<0.000 1],hemoglobin[MD=-10.34,95% CI(-15.10,-5.58),P<0.001;OR=0.28,95% CI(0.14,0.54) 0.000 2],blood platelet[MD=-20.94,95% CI(-35.63,-6.25),P=0.005],red blood cell[MD=-0.46,95% CI(-0.69,-0.23),P<0.000 1] (OR=3.88,95% CI(2.07,7.11),P<0.000 1] and life quality[OR=3.84,95% CI(2.07,7.11),P<0.000 1],with statistical significance;while had no statistical significance in lower count of bone marrow toxicity owing to blood platelet[OR=0.58,95% CI(0.27,1.21),P=0.15],neutrophils[MD=-0.10,95% CI(-0.66,0.47),P=0.73] and adverse reactions.[Conclusions] The current evidence shows that chemotherapy compound Ejiao Jiang is better to improve the peripheral hemogram and life quality after chemotherapy and is safety. However,due to the limited quality of included researches,conclusions still need to be verified by high quality researches with better design. |
|
|
|
|
|
|
|
